Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
or

Halozyme Therapeutic (HALO)

Halozyme Therapeutic (HALO)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
60.22 +2.52 (+4.37%) 04/11/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 60.22 unch (unch) 16:20 ET
Quote Overview for Fri, Apr 11th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
57.40
Day High
60.88
Open 57.87
Previous Close 57.70 57.70
Volume 1,839,800 1,839,800
Avg Vol 1,789,355 1,789,355
Stochastic %K 38.58% 38.58%
Weighted Alpha +57.70 +57.70
5-Day Change +0.45 (+0.75%) +0.45 (+0.75%)
52-Week Range 37.73 - 66.00 37.73 - 66.00
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,439,157
  • Shares Outstanding, K 123,533
  • Annual Sales, $ 1,015 M
  • Annual Income, $ 444,090 K
  • EBIT $ 623 M
  • EBITDA $ 700 M
  • 60-Month Beta 1.32
  • Price/Sales 7.02
  • Price/Cash Flow 12.40
  • Price/Book 20.18

Options Overview Details

View History
  • Implied Volatility 49.06% ( -5.27%)
  • Historical Volatility 35.23%
  • IV Percentile 96%
  • IV Rank 74.36%
  • IV High 59.09% on 04/04/25
  • IV Low 19.97% on 06/04/24
  • Put/Call Vol Ratio 0.08
  • Today's Volume 407
  • Volume Avg (30-Day) 467
  • Put/Call OI Ratio 0.40
  • Today's Open Interest 8,439
  • Open Int (30-Day) 11,265

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.90
  • Number of Estimates 4
  • High Estimate 0.98
  • Low Estimate 0.82
  • Prior Year 0.71
  • Growth Rate Est. (year over year) +26.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
55.71 +8.10%
on 04/09/25
Period Open: 61.45
66.00 -8.76%
on 03/24/25
-1.23 (-2.00%)
since 03/11/25
3-Month
52.23 +15.30%
on 01/13/25
Period Open: 52.80
66.00 -8.76%
on 03/24/25
+7.42 (+14.05%)
since 01/10/25
52-Week
37.73 +59.61%
on 04/19/24
Period Open: 39.32
66.00 -8.76%
on 03/24/25
+20.90 (+53.15%)
since 04/11/24

Most Recent Stories

More News
Halozyme Therapeutics: Q4 Earnings Snapshot

Halozyme Therapeutics: Q4 Earnings Snapshot

HALO : 60.22 (+4.37%)
Blueprint Stock Soars 18% on Encouraging 2025 Growth Strategy

Shares of Blueprint Medicines BPMC rallied 18.2% on Monday driven by investor enthusiasm following the company’s announcement of its 2025 corporate outlook and growth strategy, highlighting plans to...

CTMX : 0.5325 (+7.66%)
CSTL : 19.70 (+2.07%)
BPMC : 80.84 (+0.71%)
HALO : 60.22 (+4.37%)
PCRX Stock Rises 11% on Upbeat Q4 Preliminary Product Sales

Shares of Pacira BioSciences PCRX gained 11.1% on Friday after the company shared better-than-expected preliminary fourth-quarter 2024 sales figures for its marketed products.Additionally, the company...

CTMX : 0.5325 (+7.66%)
CSTL : 19.70 (+2.07%)
PCRX : 24.56 (+3.67%)
HALO : 60.22 (+4.37%)
SANA Stock Surges 152% in a Week on Upbeat Initial Diabetes Study Data

Shares of Sana Biotechnology SANA skyrocketed 151.5% in the past week after the company announced positive initial results from a potentially groundbreaking type 1 diabetes (T1D) study of its experimental...

CTMX : 0.5325 (+7.66%)
CSTL : 19.70 (+2.07%)
SANA : 1.7600 (+15.03%)
HALO : 60.22 (+4.37%)
Are Options Traders Betting on a Big Move in Halozyme (HALO) Stock?

Investors in Halozyme Therapeutics, Inc. HALO need to pay close attention to the stock based on moves in the options market lately. That is because the March 21, 2025 $25.00 Call had some of the highest...

HALO : 60.22 (+4.37%)
FDA Clears PCRX's New Iovera Smart Tip for Expanded Use in Pain Relief

Pacira BioSciences PCRX announced that the FDA has cleared its application to market a new Smart Tip for the iovera system designed to access the medial branch nerves to manage chronic low back pain....

CTMX : 0.5325 (+7.66%)
CSTL : 19.70 (+2.07%)
PCRX : 24.56 (+3.67%)
HALO : 60.22 (+4.37%)
Geron Stock Rallies More Than 60% in a Year: Here's Why

For Geron Corporation GERN, 2024 was a transformational year as it saw the FDA approval and commercial launch of Rytelo (imetelstat) for the treatment of low- to intermediate-1 risk myelodysplastic syndromes...

PBYI : 2.82 (+2.92%)
CSTL : 19.70 (+2.07%)
GERN : 1.3800 (+6.15%)
HALO : 60.22 (+4.37%)
HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal

Shares of Hoth Therapeutics HOTH skyrocketed 178.2% on Tuesday after the company announced positive interim safety and efficacy results from a mid-stage study of its lead candidate, HT-001, which is being...

CTMX : 0.5325 (+7.66%)
CSTL : 19.70 (+2.07%)
HOTH : 0.8008 (+0.10%)
HALO : 60.22 (+4.37%)
Here's Why You Should Consider Buying Atara Biotherapeutics Stock

Atara Biotherapeutics ATRA is a nimble allogeneic T cell immunotherapy company with several near-term catalysts. This Zacks Rank #2 (Buy) company boasts a pipeline of differentiated therapies across a...

PBYI : 2.82 (+2.92%)
CSTL : 19.70 (+2.07%)
ATRA : 5.53 (+4.34%)
HALO : 60.22 (+4.37%)
HALO Withdraws Acquisition Bid for EVO, Reaffirms '24 View, Stock Up

Halozyme Therapeutics, Inc. HALO announced that it has withdrawn its non-binding proposal to acquire Evotec SE EVO for €11.00 per share in cash. The acquisition offer implied a fully diluted equity value...

CSTL : 19.70 (+2.07%)
SPRO : 0.6000 (+3.90%)
HALO : 60.22 (+4.37%)
EVO : 3.18 (+3.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Halozyme Therapeutics Inc. is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company's ENHANZE drug delivery technology helps in developing subcutaneous formulation of drugs. The company...

See More

Key Turning Points

3rd Resistance Point 65.08
2nd Resistance Point 62.98
1st Resistance Point 61.60
Last Price 60.22
1st Support Level 58.12
2nd Support Level 56.02
3rd Support Level 54.64

See More

52-Week High 66.00
Last Price 60.22
Fibonacci 61.8% 55.20
Fibonacci 50% 51.86
Fibonacci 38.2% 48.53
52-Week Low 37.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar